-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Vir Biotechnology, Maintains $14 Price Target

Benzinga·02/09/2026 11:06:42
Listen to the news
Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $14 price target.